Diversify Wealth Management LLC Purchases 3,101 Shares of Medpace Holdings, Inc. $MEDP

Diversify Wealth Management LLC grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 93.2% in the first quarter, Holdings Channel reports. The firm owned 6,429 shares of the company’s stock after purchasing an additional 3,101 shares during the period. Diversify Wealth Management LLC’s holdings in Medpace were worth $3,087,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. BOKF NA grew its position in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares during the period. UMB Bank n.a. increased its holdings in shares of Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after buying an additional 24 shares during the period. Schulhoff & Co. Inc. boosted its holdings in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares during the period. Finally, Kaufman Rossin Wealth LLC grew its position in Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after acquiring an additional 26 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of analyst reports. Royal Bank Of Canada dropped their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Barclays cut their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Mizuho raised their target price on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research note on Monday. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $469.50.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is owned by insiders.

Medpace Stock Down 1.5%

Shares of MEDP stock opened at $530.19 on Tuesday. The business’s fifty day moving average is $469.47 and its 200 day moving average is $495.22. The stock has a market cap of $15.14 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $306.70 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.